On this page
Low HDL cholesterol
Also known as Low HDL · Low HDL cholesterol · Low good cholesterol
For most people, a low level of HDL ("good") cholesterol is not caused by a single faulty gene. Instead it reflects the additive influence of dozens of common DNA variants - in genes such as CETP, LPL and LIPC - each nudging HDL up or down by a small amount, layered on top of diet, weight, activity and other lifestyle factors.
Available at Jeen Health
Clinical tests that include this
Overview
High-density lipoprotein (HDL) cholesterol helps carry cholesterol away from the artery walls back to the liver, which is why it is often called "good" cholesterol. A persistently low HDL level is one of several lipid patterns linked to a higher risk of cardiovascular disease. In the UK, HDL is generally regarded as low below about 1.0 mmol/L in men and 1.2 mmol/L in women. Low HDL is common: in the Health Survey for England, around 11% of adults had a low HDL level, with little difference between men and women, although the exact figure varies with the threshold used. It frequently travels alongside raised triglycerides, central weight gain, type 2 diabetes and the metabolic syndrome, which is thought to affect about one in four UK adults. Low HDL rarely causes symptoms itself; it is usually picked up on a routine blood test and matters because of its contribution to long-term heart and circulatory risk.
Symptoms & clinical features
Low HDL cholesterol does not itself produce symptoms. People feel entirely well, and the level is almost always discovered through a blood test rather than because of how someone feels. Its importance lies in long-term cardiovascular risk: over years, an unfavourable lipid profile contributes to the build-up of fatty deposits in arteries, which can eventually lead to angina, heart attack or stroke. Low HDL often clusters with other features such as raised triglycerides, raised blood pressure, central (around-the-middle) weight gain and raised blood glucose. Having a higher polygenic risk does not change how low HDL or its downstream cardiovascular complications present - the clinical picture is the same. A polygenic score simply estimates the likelihood of being at the lower end of the HDL distribution, not how any future heart disease would look or feel.
Video: Genetics 101
Affected organs
Low HDL cholesterol is primarily a feature of the cardiovascular system and lipid (fat) metabolism. The liver and intestine produce and recycle HDL particles, and HDL works throughout the bloodstream to remove excess cholesterol from tissues, including the artery walls. The main clinical consequence of a low level is on the heart and blood vessels, where an unfavourable lipid balance contributes over time to atherosclerosis - the narrowing and stiffening of arteries that underlies heart attacks, strokes and peripheral arterial disease.
Risks & severity
A polygenic risk score is usually expressed as a percentile (for example, "top 10%" of genetic predisposition to low HDL) or as a relative risk compared with the average person. It describes a tendency, not a certainty: someone in a high-risk percentile may still have a normal measured HDL, and someone in a low-risk band can develop low HDL through lifestyle or other illness. It is important to be realistic about accuracy. The predictive performance of polygenic scores varies between conditions and is generally strongest in people of European ancestry, because the underlying genetic studies have been dominated by European populations. Scores tend to be less accurate for people of African, South Asian, East Asian and other ancestries, an active area of research. A polygenic score is therefore one input among many, not a verdict.
Genetic causes
Blood HDL levels are strongly heritable, with twin and family studies attributing roughly 40-60% of the variation to genetics. In most people this genetic contribution is polygenic - the sum of many common variants, each with a small effect. Genome-wide association studies (GWAS) have identified numerous robust loci. Among the best established and most influential are CETP (cholesteryl ester transfer protein), LPL (lipoprotein lipase) and LIPC (hepatic lipase), with consistent signals also at LIPG (endothelial lipase), the APOA1/C3/A4/A5 gene cluster, ABCA1, LCAT, PLTP, GALNT2 and many others. Each variant shifts HDL only slightly, but in combination they help place a person along the population's HDL distribution. A polygenic risk score sums these many small effects into a single estimate. The same genes also harbour rare, large-effect mutations that cause monogenic HDL disorders, but those are a separate, uncommon situation.
Inheritance pattern
Polygenic traits like HDL level are not inherited in the simple, predictable way of single-gene (Mendelian) conditions. There is no single variant passed down that determines whether your HDL is low. Instead, you inherit a particular mix of many common HDL-influencing variants - some from each parent - and their combined effect places you somewhere along a continuous, bell-shaped distribution of HDL levels in the population. Most people sit near the middle; a minority sit at the lower or higher ends. Because the effect is spread across so many variants, relatives can share a tendency towards low HDL without it following an obvious pattern through the family. Environment and lifestyle - weight, physical activity, smoking, alcohol and diabetes - then act on top of this inherited baseline.
Diagnosis & testing
A polygenic risk score (PRS) for HDL is an estimate, not a diagnosis. It reads many common variants across your genome and combines them, weighted by their effect on HDL in large studies, into a single number that indicates whether your inherited tendency is towards a lower or higher HDL level. It does not measure your actual cholesterol. The diagnosis of low HDL is made clinically, from a blood lipid profile - typically a fasting or non-fasting sample measuring HDL, LDL, total cholesterol and triglycerides. A polygenic score can suggest that someone is genetically predisposed to a lower HDL, which may support earlier or more attentive lipid checking, but the actual level, and any decisions about treatment, always rest on the measured blood result interpreted alongside overall cardiovascular risk.
Management & lifestyle
Because low HDL is mostly driven by lifestyle and metabolic factors acting on an inherited baseline, management focuses on the modifiable side. The most effective steps are stopping smoking, increasing regular physical activity, losing excess weight, reducing alcohol if intake is high, and improving overall diet - these can all modestly raise HDL and, more importantly, improve the whole cardiovascular picture. In the UK, low HDL is not treated in isolation. Instead, HDL feeds into overall cardiovascular risk assessment (for example the QRISK tool used in NHS primary care), which guides whether a statin or other lipid-lowering treatment is offered. Statins are prescribed to reduce overall risk rather than to raise HDL specifically; no medication reliably raises HDL with proven outcome benefit. For someone with a higher polygenic score, the practical value is earlier awareness - a prompt to have lipids checked and to act on the controllable factors sooner.
UK care pathway
The NHS does not screen for low HDL on its own. HDL is measured as part of a standard lipid profile, usually requested by a GP - for example during an NHS Health Check (offered to adults aged 40-74 in England), when assessing cardiovascular risk, or when investigating diabetes or related conditions. Results are interpreted within an overall risk calculation such as QRISK rather than treated in isolation. There is currently no routine NHS polygenic-score testing for cholesterol; any decision to start lipid-lowering treatment is based on measured lipids and total cardiovascular risk, in line with NICE guidance.
Frequently asked questions
How is polygenic low HDL different from a single faulty gene?
A single-gene (monogenic) cause is one rare, large-effect mutation - as in Tangier disease (ABCA1) or apolipoprotein A-I deficiency - that on its own drives HDL very low and follows a recognisable family pattern. Polygenic low HDL is different: no single variant is responsible. Instead, dozens of common variants in genes such as CETP, LPL and LIPC each shift your HDL slightly, and their combined effect places you on a continuous distribution. A polygenic score sums these small effects into one estimate of your inherited tendency, rather than detecting a single decisive fault.
Is a polygenic risk score for cholesterol available on the NHS?
Not routinely. The NHS measures HDL as part of a standard lipid blood test - for example during an NHS Health Check or when assessing cardiovascular risk - but it does not currently offer polygenic risk scoring for cholesterol as part of normal care. Treatment decisions are based on your measured lipid levels and overall cardiovascular risk (using tools such as QRISK), in line with NICE guidance. A polygenic score from a private test is best used to prompt earlier conversations with your GP and standard lipid checking, not to replace them.
Does a high polygenic score mean I will definitely have low HDL?
No. A polygenic score describes a tendency, not a certainty. It estimates whether your inherited make-up leans towards lower HDL, expressed as a percentile or relative risk. Someone with a high score can still have a perfectly normal measured HDL, and lifestyle factors such as smoking, weight, activity and alcohol can move your actual level in either direction. Only a blood test tells you your real HDL. The score is one piece of information that can encourage earlier checking and healthier habits.
Can I raise my HDL if my genes predispose me to a low level?
Yes, to a degree. Even with a genetic tendency towards low HDL, modifiable factors make a real difference: stopping smoking, regular physical activity, losing excess weight and moderating alcohol can all modestly raise HDL. More importantly, these steps improve your overall cardiovascular risk, which is what matters most. No medication reliably raises HDL with proven benefit, so in the UK statins and other treatments are offered to lower overall risk rather than to target HDL specifically. A higher polygenic score is best seen as a nudge to act on the controllable factors sooner.
References
- Pirillo A, Casula M, Olmastroni E. Global epidemiology of dyslipidaemias. Nature reviews. Cardiology. 2021. PMID: 33833450
- Kalra S, Raizada N. Dyslipidemia in diabetes. Indian heart journal. 2024. PMID: 37956957
- Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet (London, England). 2014. PMID: 25131982
- Van Name JP, Sharma S. Low HDL Cholesterol. 2026. PMID: 32809584
- Ferro CJ, Mark PB, Kanbay M. Lipid management in patients with chronic kidney disease. Nature reviews. Nephrology. 2018. PMID: 30361677
- Fabian D, Padda IS, Johal GS. Hypoalphalipoproteinemia. 2026. PMID: 36943964
- Nakshine VS, Thute P, Khatib MN. Increased Screen Time as a Cause of Declining Physical, Psychological Health, and Sleep Patterns: A Literary Review. Cureus. 2022. PMID: 36381869
- Wu L, Parhofer KG. Diabetic dyslipidemia. Metabolism: clinical and experimental. 2014. PMID: 25242435